TOBRADEX Eye drops, suspension (2015)
Βιβλιογραφική αναφορά
Στοιχεία εκδότη
| Εκδότης | Alcon Laboratories UK Ltd. |
|---|---|
| Διεύθυνση | Frimley Business Park, Frimley, Camberley, Surrey, GU16 7SR, United Kingdom |
Για την προβολή της πλήρους καταχώρησης απαιτείται συνδρομή σε ισχύ.
Αποκτήστε πρόσβαση σε όλες τις πληροφορίες και τα εργαλεία του Galinos.gr δωρεάν για έναν μήνα απλά κάνοντας εγγραφή.
Δωρεάν εγγραφή
Αποκτήστε πρόσβαση σε όλες τις πληροφορίες και τα εργαλεία του Galinos.gr δωρεάν για έναν μήνα απλά κάνοντας εγγραφή.
Δωρεάν εγγραφή
Pharmaceutical form
Eye Drops, Suspension. White to off-white suspension.
Qualitative and quantitative composition
Each ml contains: Tobramycin 3mg, Dexamethasone 1mg. For full list of excipients, see section 6.1
Name of the medicinal product
TOBRADEX 3mg/ml/1mg/ml Eye Drops, Suspension.
Pharmacodynamic properties
Pharmacotherapeutic group: Anti-inflammatory agents and anti-infectives in combination, corticosteroids and anti-infectives in combination ATC code: S01CA01 Dexamethasone The efficacy of corticosteroids ...
Contraindications
Hypersensitivity to tobramycin or dexamethasone or to any of the excipients listed in section 6.1 Herpes simplex keratitis Vaccinia, varicella and other viral disease of the cornea and conjunctiva Mycobacterial ...
Therapeutic indications
Prevention and treatment of inflammation and prevention of infection associated with cataract surgery in adults and children aged 2 years and older.
Fertility pregnancy and lactation
Pregnancy There are no adequate data from the use of TOBRADEX in pregnant women. Animal studies with subcutaneous administration of tobramycin have not revealed any teratogenic effects. High systemic doses ...
Posology and method of administration
Adults One drop instilled into the conjunctival sac(s) every 4 to 6 hours while the patient is awake. During the initial 24 to 48 hours, the dosage may be increased to one drop every two hours while the ...
Interaction with other medicinal products and other forms of interaction
No clinically relevant interactions have been described with topical ocular dosing. Concomitant use of topical steroids and topical NSAIDs may increase the potential for corneal healing problems.
Special warnings and precautions for use
TOBRADEX is for topical use only and not for injection or oral use. Prolonged use of topical ophthalmic corticosteroids (i.e., longer than the maximum duration used in clinical trials [24 days]) may result ...
Effects on ability to drive and use machines
TOBRADEX has no or negligible influence on the ability to drive and use machines. No studies on the effects on the ability to drive and use machines have been performed. As with any eye drop, temporarily ...
Undesirable effects
Summary of the safety profile In clinical studies involving over 1600 patients, TOBRADEX was administered up to six times daily. No serious ophthalmic or systemic adverse reactions related to TOBRADEX ...
Overdose
Due to the characteristics of this preparation, no toxic effects are to be expected with an ocular overdose of this product, or in the event of accidental ingestion of the contents of one bottle or tube. ...
Pharmacokinetic properties
Tobramycin Animal studies have shown that tobramycin is absorbed into the cornea following ocular administration. Following systemic administration to patients with normal renal function, a plasma half-life ...
Marketing authorization holder
Alcon Laboratories UK, Ltd., Frimley Business Park, Frimley, Camberley, Surrey, GU16 7SR, United Kingdom
Nature and contents of container
5ml dropper container (LDPE) and screw cap (polypropylene). Pack size: 1 5ml.
Special precautions for storage
No special precautions for storage.
Incompatibilities
Not applicable.
Preclinical safety data
The systemic toxicity profile of the individual actives is well established. Preclinical effects of tobramycin and dexamethasone were observed only at exposures considered sufficiently in excess of the ...
Special precautions for disposal and other handling
No special requirements.
Date of first authorization / renewal of the authorization
31/01/2001 / 30/04/2010
Marketing authorization number(s)
PL 00649/0119
List of excipients
Disodium edetate Hydroxyethylcellulose Benzalkonium chloride Purified water Sodium chloride Sodium sulphate anhydrous Sulphuric acid for pH adjustment and / or Sodium hydroxide for pH adjustment Tyloxapol ...
Shelf life
2 years. After the first opening of the container, the sterile ophthalmic suspension should not be used longer than four weeks.
Date of revision of the text
07 May 2015